AAAS: On the Brink of Gradual Change

WASHINGTON—Next week's annual meeting in Chicago will permit the American Association for the Advancement of Science to carry out its fundamental mission of promoting the public understanding of science. But something of even greater importance to the 139-year-old organization will take place after the meeting, when a successor to Executive Director William Carey will be announced. Carey, 70, is retiring March 31 after serving for a dozen years as head of the oldest, largest and most prest

Written byBruce Gellerman
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The last six months have been a hectic and anxious time for an organization that prefers to take a cautious, gradual approach to the myriad issues facing the scientific community. And the future poses a stern challenge to its desire to maintain a strong voice on matters of science and public policy.

Carey has put off his retirement three times in the past two years. He agreed to remain at the helm of the 132,000-member organization during a period in which its magazine for a popular audience, begun in 1979, was suffering from failing financial health.

The prolonged and secretive search for Carey's successor has been widely criticized, both by officials within the association and by outside observers. Carey said the association's board of trustees did nothing when he told them five years ago of his eventual desire to step down. Two years ago he told them "to get moving," ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies